bioMerieux (OTCMKTS:BMXMF) Receives Average Recommendation of “Reduce” from Analysts

Shares of bioMerieux (OTCMKTS:BMXMF) have received a consensus rating of “Reduce” from the six analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the company.

BMXMF has been the topic of several analyst reports. UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Piper Sandler began coverage on bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Morgan Stanley lowered bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Finally, Zacks Research cut bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st.

bioMerieux Trading Down 0.9%

Shares of BMXMF opened at $86.11 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. bioMerieux has a 12 month low of $77.00 and a 12 month high of $138.15. The company has a 50-day moving average price of $81.55 and a two-hundred day moving average price of $91.74.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.